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Background: Rheumatic fever in childhood is the most common cause of Mitral Stenosis in developing countries.
The disease is characterized by damaged and deformed mitral valves predisposing them to scarring and narrowing
(stenosis) that results in left atrial hypertrophy followed by heart failure. Presently, echocardiography is the main
imaging technique used to diagnose Mitral Stenosis. Despite the high prevalence and increased morbidity, no
biochemical indicators are available for prediction, diagnosis and management of the disease. Adopting a
proteomic approach to study Rheumatic Mitral Stenosis may therefore throw some light in this direction. In our
study, we undertook plasma proteomics of human subjects suffering from Rheumatic Mitral Stenosis (n = 6) and
Control subjects (n = 6). Six plasma samples, three each from the control and patient groups were pooled and
subjected to low abundance protein enrichment. Pooled plasma samples (crude and equalized) were then
subjected to in-solution trypsin digestion separately. Digests were analyzed using nano LC-MSE. Data was acquired
with the Protein Lynx Global Server v2.5.2 software and searches made against reviewed Homo sapiens database
(UniProtKB) for protein identification. Label-free protein quantification was performed in crude plasma only.
Results: A total of 130 proteins spanning 9–192 kDa were identified. Of these 83 proteins were common to both
groups and 34 were differentially regulated. Functional annotation of overlapping and differential proteins revealed
that more than 50% proteins are involved in inflammation and immune response. This was corroborated by
findings from pathway analysis and histopathological studies on excised tissue sections of stenotic mitral valves.
Verification of selected protein candidates by immunotechniques in crude plasma corroborated our findings from
label-free protein quantification.
Conclusions: We propose that this protein profile of blood plasma, or any of the individual proteins, could serve as
a focal point for future mechanistic studies on Mitral Stenosis. In addition, some of the proteins associated with this
disorder may be candidate biomarkers for disease diagnosis and prognosis. Our findings might help to enrich
existing knowledge on the molecular mechanisms involved in Mitral Stenosis and improve the current diagnostic
tools in the long run.
Keywords: Rheumatic fever, Mitral Stenosis, Plasma proteomics, Inflammation, Immunotechniques* Correspondence: arunb@iicb.res.in
1Cell Biology and Physiology Division, CSIR-Indian Institute of Chemical
Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, India
Full list of author information is available at the end of the article
© 2014 Mukherjee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Mukherjee et al. Clinical Proteomics 2014, 11:35 Page 2 of 18
http://www.clinicalproteomicsjournal.com/content/11/1/35Background
Acute rheumatic fever which is a sequelae of Group A
Streptococcus throat infection in genetically susceptible
individuals, remains the most common reason for
Rheumatic Heart Disease (RHD). RHD is a chronic ac-
quired heart disorder in children and young adults world-
wide [1]. It is a major public health problem in Low and
Middle Income Countries (LMICs) having a global preva-
lence of at least 15.6 million cases, with 282,000 new cases
and registering 233,000 deaths each year [2]. In India, RHD
accounts for 30-40% cardiovascular disease related hospital
admissions [3].
RHD is a post-infection autoimmune disease. It is char-
acterized by chronic inflammation of the myocardium and
heart valves in particular. Mitral valve is most commonly
affected followed by involvement of aortic valve. The tri-
cuspid and pulmonary valves are usually less affected.
RHD in mitral valve apparatus manifests most commonly
as Mitral Stenosis or Mitral Regurgitation or combination
of both producing hemodynamic burden on heart [4].
Mitral Stenosis refers to narrowing of the mitral valve
resulting in obstruction of blood flow from the left
atrium to the left ventricle. The mitral valve is damaged
and deformed predisposing it to scarring and narrowing
(stenosis) later in life. Rheumatic Mitral Stenosis is asso-
ciated with thickening of the mitral valve leaflets and fu-
sion of commissures and chordae tendineae together
with fibrosis and calcification. Hypertrophy of the left
atrium develops and may be followed by right sided
heart failure and pulmonary edema. Echocardiography is
the main imaging technique used to assess patients with
Mitral Stenosis. Symptoms usually develop when the
mitral valve area decreases below 2.5 cm2 and it is classified
as “mild” stenosis. When the mitral valve area decreases
below 1.5 cm2 it is regarded as “moderate” stenosis and
when the area diminishes below 1.0 cm2 it is termed “se-
vere” stenosis [5].
Echocardiography has an established role not only in
diagnosis but also determines severity of Mitral Stenosis of
rheumatic origin. Over the past 10 years, advances in the
quantification of valvular stenosis have occurred. These
newer techniques allow for the differentiation of mild from
moderate and moderate from severe disease. However it is
costly in countries with the highest disease burden and only
available in limited tertiary health care facilities. In such re-
gions, echocardiographic screening might be considered lo-
gistically unfeasible or secondary prophylaxis insufficiently
developed to recommend screening. Moreover, being a
highly operator/technician dependent imaging modality,
there is a considerable chance of over or under-diagnosis of
Rheumatic Mitral Stenosis with echocardiography alone.
Technical pitfalls of image acquisition and echocardio-
graphic machine settings must always be addressed as
image quality can substantially affect the interpretation ofimages. A lack of adequate number of experts in echocar-
diographic diagnosis of Rheumatic Mitral Stenosis in en-
demic countries like India will prevent detection of subtle
echocardiographic features as well. So the best strategy may
be a combined echocardiographic and biomarker based ap-
proach to predict, diagnose and manage chronic Rheumatic
Mitral Stenosis.
In recent years proteomics has emerged as a novel tech-
nology that has been extensively applied to cardiovascular
disease research with the aim to understand the disease
mechanisms. Adopting a proteomic approach to study the
pathogenesis of Rheumatic Mitral Stenosis may throw
some light on how the disease develops, since samples
from various sources can be analyzed, like tissues, body
fluids and circulating cells. In the present study we ana-
lyzed the proteome of plasma, a very useful clinical source
for proteomic analysis in various pathologies. Plasma is an
ideal biological sample due to its accessibility [6]. More-
over, as blood circulates through every organ and tissue of
the body, it contains valuable information pertaining to
the different physiological and pathological states of the
organism [7]. The circulatory system thus provides a
unique repertoire of proteins shed by cells and tissues that
can potentially be used to assess both normal and disease
conditions.
However, plasma is one of the most complex body fluids
with a wide dynamic range of protein concentrations (9–
10 orders). This presents an extreme analytical challenge
in characterization of the plasma proteome as highly
abundant proteins tend to mask low abundant ones [8].
This complexity exceeds the analytical capability of most
proteomic approaches. For this reason, plasma analysis re-
quires pre-fractionation. Saturation protein binding to a
combinatorial peptide ligand library (CPLL) in combin-
ation with mass spectrometry has recently gained import-
ance in analyzing the plasma proteome as an alternative
approach to the more traditional and widely used method
of “immunodepletion” [9-14].
To date, no proteomic study has investigated the differ-
ence between stenotic and non stenotic human plasma
proteins in the context of Rheumatic Mitral Valve disease.
In the present study, by adopting a label free proteomic
approach we therefore analyzed the protein profile in con-
trol and patient plasma. Our results highlight that Rheum-
atic Mitral Stenosis is an active inflammatory process
which manifests both inflammatory and thrombotic com-
ponents. New information about these proteins will elab-




Figure 1 presents an overview of the proteomic work-
flow adopted in the study.
Figure 1 Scheme depicting study design. Pooled plasma samples isolated from peripheral venous blood of controls and patients are
processed and analyzed as outlined in the chart.
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Baseline characteristics of control and patient subjects
are shown in Table 1. Diastolic blood pressure, left atrial
(LA) diameter and left ventricular ejection fraction were
found to be significantly different in the patient group
than the control group. In fact, left atrial enlargement as
understood from the LA diameter is most common in
patients with chronic Rheumatic Mitral Stenosis. Pa-
tients and control subjects were age and sex matched.
As shown in Table 2, 66% of the patients recruited in
the study had history of rheumatic fever in childhood
and 34% had atrial fibrillation. 46% of the patients
belonged to New York Heart Association (NYHA) class
I, 31% belonged to class II, 17% in class III and the
remaining 6% in class IV. Drugs administered to patients
in the study are shown (Table 3). Around 2% of the pa-
tients were taking diuretics, 71% digoxin, 31% aldactone,
around 6% ACE inhibitors and 20% were taking beta
blockers. Almost 51% of the patients were under anti-
coagulant (warfarin) therapy. All patients included in the
study were under rigorous penicillin prophylaxis to pre-
vent recurrent episodes of Acute Rheumatic Fever.
Proteomics findings
For analyzing crude and pre-fractionated plasma, stenotic
and non-stenotic plasma samples were selected for prote-
omic analysis by nanoLC-MSE. This led to the identifica-
tion of 130 proteins covering a range of molecular masses
spanning 9–192 kDa and a pI range covering 4.4-9.8 (see
Additional file 1 and Additional file 2). All these proteins
were identified in at least two of the three technical repli-
cates with two or more peptides matched. A total of 106
proteins were identified in pooled samples of the control
group and 107 proteins in pooled samples of the patient
group respectively. Of these, 83 were common to bothcontrol and patient groups (Figure 2A). However 23 pro-
teins were unique to the control group and 24 proteins to
the patient group.
Among the proteins identified in this comparative pro-
teomics study, 34 proteins were found to be differentially
abundant. Immunoglobulin heavy chains like α, γ and
light chains κ and λ were significantly downregulated (i.
e.; abundance of these protein species were higher in
controls than patients) in Mitral Stenosis group. Com-
plement proteins like C3, C4A, isoform 2 of comple-
ment C4A, C4B, complement C4b binding protein α
chain, complement factor B, complement factor H were
also found to be significantly downregulated in the patient
group. Other proteins like α-1-acid glycoprotein I, α-2-
macroglobulin, α-2-HS-glycoprotein, ceruloplasmin, α-1-
antitrypsin, α-1-antichymotrypsin, haptoglobin, haptoglobin
related protein were all downregulated. Among the apoli-
poproteins, Apo AI and Apo CIII were significantly down-
regulated (2.1-fold and 2.5-fold respectively) in patients.
Also, isoform 2 of fibrinogen α chain, fibrinogen β chain as
well as isoform γA of fibrinogen γ chain were significantly
downregulated by 1.9-fold, 2.5-fold and 2.7- fold respect-
ively in the patient group (Table 4).
Functional annotation of profiled proteins
The 83 proteins common to both the groups and the 34
proteins found to be differentially altered were classified
by functional annotation. In both cases, the majority of
proteins could be classified into 4 different functional
categories directly associated with important biological
processes in the cardiovascular system: Inflammation
and Immune response; Blood homeostasis and coagula-
tion; Lipid Metabolism; Transport and Others (Figure 2B
and 2C). These functional categories were mainly deter-
mined using the Swiss-Prot database. The proportion of
Table 1 Baseline Characteristics of Controls and Mitral Stenosis patients
Variables Control (n = 19) Rheumatic MS (n = 35) p value
Age (years) 32.68 ± 1.77 (n = 19) 36.74 ± 1.43 (n = 35) 0.11
Male / Female 12 / 7 20 / 15 0.78
Clinical Presentation data
Pulse (bpm) 76 ± 1.82 78.37 ± 2.77 (n = 35) 0.96
SBP (mmHg) 119.79 ± 3.03 114.86 ± 2.60 (n = 35) 0.29
DBP (mmHg) 82.26 ± 1.42 75.60 ± 2.15 (n = 35) 0.03
Echocardiographic parameters (Normal range)
LA (20 – 40 mm) 30.88 ± 0.85 (n = 17) 48.58 ± 1.44 (n = 32) <0.0001
LVIDd (35–56 mm) 43.53 ± 1.12 (n = 17) 44.77 ± 1.23 (n = 35) 0.52
LVIDs (24 - 42 mm) 29.24 ± 0.79 (n =17) 30.99 ± 0.93 (n = 35) 0.23
LVPW (6 -11 mm) 8.35 ± 0.26 (n = 17) 8.63 ± 0.26 (n = 32) 0.32
IVSD (6–11 mm) 8.53 ± 0.23 (n = 17) 9.11 ± 0.26 (n = 33) 0.12
EF (%) 66.82 ± 0.83 (n = 17) 56.80 ± 1.16 (n = 35) <0.0001
PASP (mmHg) - 57.32 ± 4.22 (n = 22) NA
MVA (sq.mm) - 87 ± 4 (n = 33) NA
Fractional shortening (%) 32.73 ± 1.04 (n = 17) 30.71 ± 0.94 (n = 35) 0.19
bpm beats per minute, EF ejection fraction, IVSD interventricular septal diameter, LA left atrium, LVIDd left ventricular internal diameter diastolic, LVIDs left
ventricular internal diameter systolic, LVPW left ventricular posterior wall, MVA mitral valve area, n number of subjects, NA not applicable, NYHA New York Heart
Association, PASP pulmonary artery systolic pressure, SBP systolic blood pressure. Values indicate mean ± standard error of mean. p < 0.05 considered statistically
significant between two groups.
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55% in the overlapping group to about 70% in the differ-
entially regulated group.
Network connections of proteins for further
investigations
As seen in Figure 3, differential proteins like comple-
ment factor B, complement factor H, C4b binding pro-
tein α chain, orosomucoid I or α-1-acid glycoprotein I,
α-1-antitrypsin, α-2-macroglobulin, haptoglobin, ceru-
loplasmin, albumin, apolipoproteins AI and CIII to-
gether with the fibrinogens were highly networked.
Another set of proteins forming a novel module of net-
work included the various immunoglobulin variants.
These kinds of networks suggest the collaborative inter-
actions between several protein candidates; in this case,
of common proteins and/or differential proteins.
Quantification of selected marker candidates in crude
plasma samples by colorimetric ELISA
To assess the performance of the potential marker can-
didates identified by nano LC-MSE analysis, their abun-
dance in crude plasma of individual control and patient
subjects were determined by immunoassay (ELISA or
immunoturbidimetry). Several criteria were used to
select potential candidates for ELISA validation. The
protein candidates had to fulfill the following: (1) identi-
fication of the selected protein candidates in triplicateruns in both crude and equalized pooled plasma of pa-
tient and healthy subjects; (2) difference in levels should
be statistically significant i.e., p < 0.05 and consistent regula-
tion in all the replicate analyses; (3) potential biological rele-
vance of these proteins to heart valve and/or cardiovascular
disease based on information obtained from functional an-
notation of identified proteins and manual literature search
of publications and lastly; (4) the availability of commer-
cially available ELISA kits or primary antibodies. As half of
the patients were on anticoagulant therapy, many of the
candidate markers of coagulation or some of the protease
inhibitors known to be involved in the coagulation cascade,
could not be validated as this could have led to erroneous
estimation of their circulating levels under the disease con-
dition. Plasma α-2- HS-glycoprotein concentration was sig-
nificantly lower in stenotic subjects than controls (818.3 ±
66.8 vs. 646.8 ± 43.5 μg/ml, p = 0.03; unpaired t-test;
Figure 4A). Plasma level of apolipoprotein AI was also sig-
nificantly lower in patients with Mitral Stenosis than
healthy control subjects (1390.8 ± 33.1 vs.1166.2 ±
78.2 μg/ml, p = 0.02; unpaired t-test; Figure 4B). From
the network map of the common and differential pro-
teins in Figure 3, it is seen that apolipoprotein AI is
predicted to interact with proteins like vitronectin and
clusterin which have also been identified in control and
patient plasma in this study. Hence, to check their sta-
tus in chronic Mitral Stenosis, circulating levels of
these proteins were also measured by quantitative
Table 2 Clinical Characteristics of patients with Rheumatic Mitral Stenosis
Patient Age Sex h/o RF NYHA Pulse AF SBP DBP Type of MS
P1 41 M Y I 80 N 120 70 Severe MS + Moderate AR
P2 42 F N II 88 Y 110 80 severe MS +Moderate MR +mild AR
P3 45 M Y I 72 N 130 90 Severe MS + Moderate MR +Mild AS +Moderate TR
P4 35 M Y I 60 N 110 60 Severe MS + Moderate AR +Moderate TR +Mild MR
P5 24 M N I 78 Y 110 66 Severe MS + Moderate MR
P6 26 M N I 78 N 120 90 Moderate MS + Mild AR
P7 33 F Y I 78 N 130 90 Severe MS + Mild AR
P8 35 M Y I 60 Y 120 90 Severe MS + Moderate TR + Mild MR
P9 45 F Y III 77 N 100 70 Severe MS
P10 35 M N III 80 N 100 60 Moderate MS
P11 33 M N I 66 N 100 80 Severe MS + Mild MR +Mild TR + Mild AS
P12 36 F Y IV 84 N 110 60 Severe MS + Severe TR
P13 48 M Y I 84 N 120 80 Severe MS
P14 25 F Y I 70 Y 100 60 Severe MS
P15 35 F N I 96 N 100 70 Severe MS + Mild TR
P16 32 F N I 58 Y 80 50 Severe MS
P17 55 M N II 60 Y 140 80 Severe MS
P18 33 F Y I 76 N 100 70 Severe MS + Mild MR
P19 40 F N I 108 N 110 80 Severe MS
P20 19 M N I 70 N 100 70 Severe MS
P21 38 F Y I 64 Y 80 50 Severe MS + Mild MR +Moderate AR
P22 42 M Y III 64 N 140 100 Severe MS + Moderate AS + Moderate AR
P23 24 F Y III 120 N 110 80 Severe MS + Moderate AS
P24 27 M Y II 62 Y 130 100 Severe MS + Mild MR
P25 48 M Y II 100 N 140 100 Severe MS + Moderate TR
P26 40 F Y III 80 N 110 70 Severe MS + Mild MR
P27 28 M Y II 70 N 110 70 Severe MS + Moderate MR
P28 35 F Y II 80 Y 120 80 Severe MS + Moderate TR + Mild MR
P29 43 F Y II 100 Y 120 80 Severe MS + Severe TR + Moderate AR
P30 35 M Y II 100 Y 120 70 Severe MS + Moderate AR
P31 50 M Y II 80 N 130 70 Severe MS + Moderate AS +Moderate AR
P32 47 F Y II 110 N 130 80 Severe MS + Moderate MR +Moderate TR + Moderate AR
P33 46 M Y IV 50 Y 140 80 Severe MS + Mild MR + Severe TR
P34 30 M N III 60 N 120 80 Moderate MS + Mild AR
P35 36 M N II 80 N 110 70 Severe MS + Mild AR + Severe TR
AF atrial fibrillation, AR aortic regurgitation, AS aortic stenosis, bpm beats per minute, DBP diastolic blood pressure, F female, h/o RF history of Rheumatic Fever, M
male, MR mitral regurgitation, MS mitral stenosis, N no, NYHA new york heart association, P patient, SBP systolic blood pressure, TR tricuspid regurgitation.
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in patients than control subjects (317.4 ± 31.1vs.178.2 ±
17.5 μg/ml, p < 0.0001; unpaired t-test; Figure 4C).
Lastly, plasma level of vitronectin was also signifi-
cantly lower in patients with Mitral Stenosis than con-
trol subjects (68.2 ± 6.2 vs. 47.9 ± 4.5 μg/ml, p = 0.01;
Figure 4D).Identification of pathways associated with Rheumatic
Mitral Stenosis
Pathway analysis for the common and differentially
abundant proteins in Rheumatic Mitral Stenosis re-
vealed that about 18 of them belong to the complement
and coagulation cascade (Figure 5). This is relevant in
the context of the present study since chronic
Table 3 Medications taken by Mitral Stenosis patients during the study
Number Diuretic Lanoxin Aldactone ACE inhibitor Beta blocker Warfarin
P1. Y Y Y
P2. Y Y Y Y
P3. Y Y Y
P4. Y Y Y
P5. Y Y Y
P6. Y Y Y
P7. Y Y
P8. Y Y Y
P9. Y Y Y Y
P10. Y Y Y Y
P11.
P12. Y
P13. Y Y Y Y Y
P14. Y Y
P15. Y
P16. Y Y Y
P17. Y
P18. Y Y Y Y
P19. Y Y
P20. Y Y Y Y
P21. Y







P29. Y Y Y
P30. Y Y Y
P31. Y Y Y
P32. Y Y Y
P33. Y Y Y
P34. Y Y
P35. Y Y Y
ACE inhibitor Angiotensin Converting Enzyme inhibitor, P Patient, Y Yes.
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flammatory state.
Histopathology analysis
Microscopic examination of hematoxylin - eosin (HE)
stained mitral valve sections from Rheumatic Mitral
Stenosis subjects showed enhanced degree of fibrosisand neovascularization (arrows marked in Figure 6).
Focal perivascular mild infiltration of lymphocytes and
abundant plasma cells were prominent, thus confirming
inflammatory aetiology in those subjects, consistent
with the findings from pathway analysis as well as from
functional annotation of profiled proteins. In contrast,
normal mitral valve was composed of loose collagen
Figure 2 Proteomics findings. (A) Venn diagram comparing the number of identified proteins for the six biological replicates and their
relationship. The numbers of proteins detected with at least two peptides are indicated by numbers. (B) Pie chart representing the distribution of
identified proteins in the common or overlapping group according to their biological function. (C) Pie chart representing the distribution of
identified proteins in the differentially altered group according to their biological function. Assignments are made on the basis of information
provided by Swiss-Prot.
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(Figure 6).
Discussion
The aim of the present study was to provide a better un-
derstanding of the pathophysiological mechanisms in-
volved in Rheumatic Mitral Stenosis. To accomplish this,
we performed two distinct analyses - using crude plasma
and a different strategy to reduce the complexity of the
plasma proteome (equalization). To our knowledge, most
of the proteins identified in this study have not been previ-
ously described in the context of Rheumatic Mitral
Stenosis.
To increase the detectable proteome dynamic range
we used an alternative pre-fractionation method, CPLL -
a technology designed for sample equalization by using a
combinatorial library of hexapeptides bound to a chro-
matographic support. Plasma equalization reveals pro-
teins that are not detected in crude plasma samples like
serum amyloid A4, lipopolysaccharide binding protein,
vitamin K dependent protein S, paraoxonase 1 and so
on. Although plasma equalization combined with the
power of nano LC-MSE helps to uncover less abundant
proteins like ficolin 3 (21.6 μg/ml) [15], sex hormone
binding globulin (8.1 ng/ml) [16] and angiotensinogen
(1.5 μg/ml) [17], the depth of proteome coverage is low.
However, many of the abundant proteins particularly
much of the immunoglobulins, α-1-acid glycoprotein, α-
2-macroglobulin, haptoglobin and serotransferrin are
lost in this approach.
To further understand the significance of a plethora of
proteins that may appear in the plasma in response todiverse physiological events in Mitral Stenosis, we com-
pared the protein abundance patterns in crude plasma
between Rheumatic Mitral Stenosis patients and normal
controls using label-free proteomic technique. We iden-
tified 34 differential proteins which are downregulated
in the plasma of patients. Proteins that are differentially
abundant between the two groups are potential sero-
logical biomarkers for Mitral Stenosis. In addition, pro-
teins that are differentially abundant in patients could
reflect pathophysiological changes arising from abnor-
mal mitral valve structure and function. These proteins
may be used for diagnosis and disease monitoring.
To gain insight into the biological significance of the
altered and the common proteins in the disease, the dif-
ferentially abundant and overlapping proteins are cate-
gorized according to their reported biological functions.
Functional characterization of these proteins of interest
reveal that more than 50% are involved in inflammation
and immune response. This is corroborated by findings
from pathway analysis as well as from histopathological
studies on excised tissue sections of stenotic mitral
valves. Interestingly, evidences of chronic inflammation
with cellular infiltration have been previously reported
by several authors in aortic stenotic valves [18,19].
Most of the differences are found in proteins related
with Inflammation and Immune response in the present
study. Alterations in the complement system proteins
particularly downregulation of C4A and its isoform,
C4B, complement factor H, complement factor B, C3
and C4b binding protein α chain along with several
forms of immunoglobulins are observed in plasma of
Mitral Stenosis patients in the label free protein
Table 4 Differentially abundant proteins found in the proteomic analysis
Swiss-prot accession number Protein name Ratio [Patient/Control] p value
P02763 Alpha 1 acid glycoprotein I 0.15 <0.05
P01011 Alpha 1 antichymotrypsin 0.60 0.01
P01009 Alpha 1 antitrypsin 0.32 <0.05
P02765 Alpha 2 HS glycoprotein 0.71 0.02
P01023 Alpha 2 macroglobulin 0.56 <0.05
P02647 Apolipoprotein A I 0.47 <0.05
P02656 Apolipoprotein C III 0.39 0.02
P04003 C4b binding protein alpha chain 0.29 <0.05
P00450 Ceruloplasmin 0.66 <0.05
P01024 Complement C3 0.67 <0.05
P0C0L4 Complement C4 A 0.64 <0.05
P0C0L5 Complement C4 B 0.69 <0.05
P00751 Complement factor B 0.46 <0.05
P08603 Complement factor H 0.41 <0.05
P02675 Fibrinogen beta chain 0.39 <0.05
P00738 Haptoglobin 0.21 <0.05
P00739 Haptoglobin related protein 0.33 <0.05
P01876 Ig alpha 1 chain C region 0.23 <0.05
P01877 Ig alpha 2 chain C region 0.61 <0.05
P01857 Ig gamma 1 chain C region 0.87 <0.05
P01859 Ig gamma 2 chain C region 0.38 <0.05
P01860 Ig gamma 3 chain C region 0.06 <0.05
P01861 Ig gamma 4 chain C region 0.84 <0.05
P01777 Ig heavy chain V III region TEI 0.60 0.02
P01834 Ig kappa chain C region 0.38 <0.05
P01620 Ig kappa chain V III region SIE 0.46 <0.05
P0CG04 Ig lambda 1 chain C regions 0.09 <0.05
P0CG05 Ig lambda 2 chain C regions 0.54 <0.05
P0CG06 Ig lambda 3 chain C regions 0.10 <0.05
P01871 Ig mu chain C region 0.42 <0.05
P0C0L4-2 Isoform 2 of Complement C4 A 0.64 <0.05
P02671-2 Isoform 2 of Fibrinogen alpha chain 0.53 <0.05
P02679-2 Isoform Gamma A of Fibrinogen gamma chain 0.37 <0.05
P02768 Serum albumin 0.83 0.0004
Three nano LC-MSE analyses of the plasma samples were performed for protein identification and relative quantification.
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important component of humoral autoimmunity in the
natural defense mechanism in man. The system is not
only vital for host defense against infectious diseases, it
also plays an important role in protection, development,
and progression of inflammatory diseases including many
rheumatic disorders [20]. The presence of complement C1
proteins and C3 molecule clearly shows that both the
‘classical’ and ‘alternate’ pathways are operational in the
disease process. Complement C4, an essential componentof the humoral immune response, plays a central role in
the activation of the classical and lectin pathways of the
complement system. Chronic infections can initiate for-
mation of immune complexes, causing continuous activa-
tion and consumption of complement [21]. This may be
the reason for the lower abundances of C3, C4A, C4B and
C4b binding protein α chain observed in Mitral Stenosis
patients. In fact, low C4b copy number carrier status has
been reported in patients with acute myocardial infarction
and stroke [22]. The identification of proteins such as
Figure 3 Biological network of reported proteins associated with Rheumatic Mitral Stenosis. Proteins marked by red circles indicate
differentially abundant proteins. Proteins indicated by green circles have not been found to be differentially abundant in the proteomic phase but
were found to be so in the verification phase of the study. AHSG, α-2-HS- glycoprotein; A2M,α-2-macroglobulin; ALB,albumin; APOA1,Apolipoprotein
AI; APOC3,apolipoprotein CIII; CP,ceruloplasmin; CLU,clusterin; C3,complement component 3; C4A,complement component 4A; C4BPA,complement
component 4 binding protein α; CFB,complement factor B; CFH,complement factor H; FGA,fibrinogen α chain; FGB,fibrinogen β chain; FGG,fibrinogen
γ chain; HP,haptoglobin; HPR,haptoglobin related protein; IGHA1,Ig alpha-1 chain C region; IGHA2,Ig alpha-2 chain C region; IGHG1,Ig gamma-1chain
C region (G1m marker); IGHG2,Ig gamma-2 chain C region (G2m marker); IGHG3,Ig gamma-3 chain C region (G3m marker); IGHG4,Ig gamma-4 chain C
region (G4m marker); IGK@,Ig kappa chain C region; IGKV4-1,Ig kappa chain variable 4–1; IGLC1,Ig lambda-1chain C region; IGLC2,Ig lambda-2 chain C
region; ORM1,orosomucoid 1 or α-1-acid glycoprotein 1; SERPIN A1,serpin peptidase inhibitor, clade A member 1 or α-1-antitrypsin; SERPIN A3,serpin
peptidase inhibitor, clade A member 3 or α-1-antichymotrypsin; VTN,vitronectin
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bind some complement components ficolin 3 (collagen/fi-
brinogen domain containing lectin 3p35) and galectin 3
binding protein (basement membrane autoantigen p105
or lectin galactoside binding soluble 3 binding protein) in
patients together point to the fact that possibly the lectin
pathway of complement also plays a role in the patho-
physiology of Rheumatic Mitral Stenosis. All these data
suggest that there is a strong innate response in Mitral
Stenosis. Thus it is an active inflammatory process that
could lead to a prothrombotic state.
It is known that protease inhibitors and proteases play
crucial roles in various physiologic functions as blood
homeostasis and coagulation, transport, extracellular matrix
turnover and tissue remodelling as well as triggering or
modulating inflammatory processes in pathologic situa-
tions. Some of these proteins (α-1-antichymotrypsin, α-1-
antitrypsin, inter α trypsin inhibitors, protein AMBP) had
previously been implicated in atherosclerosis, aortic valvestenosis and other cardiovascular diseases [23-25]. Our ana-
lysis detects this group of proteins in Mitral Stenosis pa-
tients. Serine protease inhibitors (SERPINs) represent a
major regulatory mechanism controlling enzyme activity of
activated coagulation factors. Under normal blood circula-
tion conditions, these proteins are present in sufficient con-
centrations to further down-regulate the various clotting
factors thereby acting as security against random activation
of thrombin or other proteases and the resulting fibrin
clots. Serpins such as antithrombin III (SERPIN C1) and
heparin cofactor II (SERPIN D1) have been detected in the
present study. Both the proteins possess anticoagulant
properties as they tightly bind and inactivate thrombin.
We also show a downregulation of circulating anti-
proteases like α-1-antichymotrypsin (SERPIN A3) and α-
1-antitrypsin (SERPIN A1) perhaps pointing to the de-
velopment of a more prothrombotic state in Rheumatic
Mitral Stenosis. This pro-coagulant effect may limit in-
fection by trapping pathogens in local blood clots. A
Figure 4 Verification of selected protein candidates in normal and Mitral Stenosis subjects. Plasma concentration of (A) α-2-HS-glycoprotein or
fetuin A, (B) apolipoprotein AI, (C) clusterin and (D) vitronectin. Statistical significance is determined by unpaired, two-tailed Student’s t-test (*signifies
p < 0.05 vs. control and **signifies p < 0.01 vs. control). Data represent mean ± SEM.
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leading to a local prothrombotic state of the aortic
valve, has been previously reported [26]. We demon-
strate a reduced abundance of proteins involved in
blood homeostasis and coagulation particularly fibrino-
gen. Prothrombin is a serine protease that is synthesized
in the liver and contains 10 Gla residues in its amino-
terminal domain. Factor Xa cleaves prothrombin into its
activated form thrombin. Thrombin in turn acts as a
serine protease that converts soluble fibrinogen into insol-
uble strands of fibrin, as well as catalyzing many other
coagulation-related reactions. Endogenous coagulation in-
hibitors like vitamin K dependent protein S, a cofactor of
protein C are also detected in this study. Protein C is a
Gla containing protease which when activated can proteo-
lytically cleave Factors Va and VIIIa together with its co-
factor protein S. Proteolysis can, therefore, be a method of
regulating biological processes by turning inactive proteins
into active ones.
In addition to abundance, post-translational modifica-
tions also have illustrated roles in governing activities of
certain blood clotting factors. Synthesis of a uniquemodified glutamate residue called carboxyglutamate
(Gla) results from post-translational modifications of
newly synthesized inactive coagulation factors like Pro-
thrombin in the liver endoplasmic reticulum by a
vitamin K-dependent carboxylase [27]. This is termed as
γ carboxylation which is an irreversible posttranslational
modification that plays a role in the effective functioning
of blood coagulation factors. In gamma-carboxylation, a
carboxyl group is attached to certain Glu side chains of
the protein resulting in the conversion of Glu to γ –car-
boxyglutamate (Gla). Phosphorylation of prothrombin
has also been observed. Hence, our data in this study in-
dicates an important deregulation or impaired function
of proteases, anti-proteases and coagulation proteins in
Mitral Stenosis development.
In our analysis, we detected several apolipoproteins
(Apo AI, Apo AII, Apo AIV, Apo CI, Apo CII, Apo CIII,
Apo D, Apo E) in control and patient plasma. In
addition, we found alterations in the abundances of apo-
lipoproteins AI and CIII in the “proteomic” phase of the
study. Apolipoprotein AI is one of the dominant pro-
teins in high density lipoprotein (HDL) but the other
Figure 5 (See legend on next page.)
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Figure 5 Identification of pathways associated with Rheumatic Mitral Stenosis. Proteins marked by red circles indicate those that are found to
be differentially abundant and/or common to the control and patient groups. Proteins indicated by blue circles are identified only in the patient
group. A2M, α-2-macroglobulin; BF, complement factor B; C1Q, complement component 1,q subcomponent; C1S, complement component 1, s
subcomponent; C3,complement component 3; C4,complement component C4; C4BP, complement component 4 binding protein; C9, complement
component C9; F2,coagulation factor II or prothrombin; FG, fibrinogen; HF1,complement factor H; KNG, kininogen 1; PLG, plasminogen; PROS1,protein
S α; SERPIN A1,serpin peptidase inhibitor, clade A member 1 or α-1-antitrypsin; SERPINC1,serpin peptidase inhibitor, clade C, member 1 or antithrombin
III; SERPIND1,serpin peptidase inhibitor, clade D, member 1or heparin cofactor II; SERPING1,serpin peptidase inhibitor, clade G, member 1 or C1
inhibitor.
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been described as HDL components [28]. Recently a
proteomic study has reported that HDL carries protein
families implicated in complement activation, regulation
of proteolysis, and acute-phase response [29]. It is
further known that under inflammatory conditions anti
inflammatory proteins such as paraoxonase 1 and clus-
terin are displaced from HDL by proinflammatory ones
like serum amyloid A and haptoglobin. Thus anti-
inflammatory HDL turns proinflammatory which is also
called dysfunctional HDL [30]. All these signify that
HDL may serve as a link between lipid metabolism, in-
flammation and mitral valve disorder of rheumatic eti-
ology. This is an interesting aspect of this disease that
has not been studied much so far but will be the pursuit
of future investigations. It is believed that oxidation of low
density lipoprotein in blood leads to heart ailments. The
presence of glutathione peroxidase 3 in equalized plasma
of Rheumatic Mitral Stenosis raises the possibility of a
protective role in this pathology, since it modulates oxida-
tive stress by increasing resistance of cells to such kind of
vascular injury. Structural proteins like fibulin 1 and gelso-
lin together with its isoform in Rheumatic Mitral Stenosis
point to the fact that possibly cells undergo structural re-
modelling both in terms of cytoskeletal elements and
extracellular matrix. This group of proteins is totally non-Figure 6 Histopathological analysis. Representative images (100 X magnifi
(control) and 3 stenotic mitral valve samples (RHD). Rheumatic mitral valve tis
fibrosis (green arrow) and neovascularization (black arrow). Normal mitral valv
arrow).existent in the control group. However further in-depth
studies are warranted to substantiate these preliminary
observations.
We focused on choosing common and differential pro-
tein candidates to develop a predictive network model
for further biological investigation using Search Tool for
the Retrieval of Interacting Genes/Proteins (STRING)
database. This was done using data from biological func-
tions of local networks surrounding the protein candi-
dates [31-34]. In addition, to verify the findings from the
pilot phase we have tested the abundance of a panel of
four candidate serum proteins (α-2-HS-glycoprotein,
apolipoprotein AI, clusterin and vitronectin) by immu-
noassays. The results confirm that the mean plasma level
of these candidate proteins in Mitral Stenosis patients
are significantly altered compared to controls.
Human fetuin A, also known as α-2-Heremans-Schmid
glycoprotein, is a member of the cystatin superfamily of
cysteine protease inhibitors. Plasma α-2-HS-glycoprotein
is mainly produced by hepatocytes and monocytes/mac-
rophages and is involved in inflammation [35,36]. Serum
α-2-HS-glycoprotein levels are associated with valvular
calcification in patients suffering from end-stage renal dis-
ease [37]. An inverse association between serum α-2-HS-
glycoprotein levels and the prevalence of Aortic Valve
Stenosis in non-diabetic patients, but not in diabeticcation) of hematoxylin-eosin stained sections of 1 normal mitral valve
sue section shows abundance of inflammatory cells (white arrow head),
e section is devoid of inflammatory cells and neovascularization (black
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“label free” proteomic technique, a significant downregula-
tion of α-2-HS-glycoprotein by about 1.4-fold is seen in
plasma of Mitral Stenosis patients. Verification studies also
reveal significantly diminished plasma α-2-HS-glycoprotein
levels in Mitral Stenosis subjects compared to controls. Re-
cently lower serum α-2-HS-glycoprotein levels have been
reported in Turkish patients with Rheumatic Mitral Valve
disease [39]. This could be because the synthesis of α-2-
HS-glycoprotein remains downregulated during injury and
inflammation. This may also suggest that α-2-HS-glycopro-
tein plays a significant role in mitral valve calcification since
it acts as an endogenous inhibitor of ectopic calcification.
Hence a downregulation of α-2-HS-glycoprotein might lead
to improper mineralization by accelerating calcium salt de-
position in stenotic mitral valves.
Apolipoprotein AI, a single polypeptide is a major
component of HDLs. Several cardioprotective effects of
HDL have been attributed to Apo AI. In our verification
experiments, apolipoprotein AI levels are significantly
lower in Rheumatic Mitral Stenosis subjects compared
to controls probably because of decreased protein syn-
thesis, accelerated HDL catabolism and Apo AI replace-
ment by serum amyloid A [40] or the persistence of a
chronic inflammation. Apo AI is also well known for its
anti-inflammatory properties [41,42]. Clusterin or apoli-
poprotein J is a secreted multifunctional protein that
was named for its ability to induce cellular clustering. It
may function as a chaperone of misfolded extracellular
proteins. Apo J has been suggested to have anti-
inflammatory [43], cytoprotective [44,45] and antiapop-
totic properties [46]. Experimental evidence suggests
that clusterin or Apo J interacts with Apo AI in vitro
which could be physiologically important [47]. In the
present study, plasma clusterin levels differed signifi-
cantly between the control and patient groups.
Vitronectin (VN), or serum spreading factor and be-
longing to the group of Arg-Gly-Asp (RGD) type of cell
adhesion glycoprotein in plasma, regulates the immune
and hemostatic systems particularly at the blood-
endothelium interface [48]. Through binding to different
integrins, VN may directly interact with endothelial cells
and platelets [49-51]. In our study, plasma vitronectin
levels are found to be significantly lower in Mitral Stenosis
subjects compared to controls. This may imply reduced
protection against complement sublytic and lytic attacks
as both clusterin and vitronectin are known to regulate
the complement pathway by inhibiting complement me-
diated cell lysis [52]. Very recently, reduced plasma
vitronectin concentrations have been observed in Rheum-
atic Valvular Disease subjects in a Chinese population [53].
In addition, vitronectin plays a role in avian cardiac
valve development [54]. Taken together, the findings from
the present study indicate that concentration changein vitronectin might be related to valvular pathological
changes and may also indicate likely genetic defects in such
patients.
The present findings are based on a limited number of
representative patient samples. A larger multi-centric popu-
lation would have been more effective for the verification
studies. Again, the present study provided description of
the changes in Mitral Stenosis at protein level only. Con-
founding factors of the disease like age, left atrial diameter,
mitral valve area and pulmonary artery systolic pressure
may influence alteration of proteins in Mitral Stenosis.
Moreover, plasma proteins at high and medium concentra-
tions were mainly detected using this approach. Many other
proteins in the ng/ml range like cytokines, small peptides
and growth factors were not detected. However, it is be-
lieved that the more abundant proteins could play an im-
portant role in the development of valvular disorders and
as such, their abundances may be altered in pathological
circumstances. As expected, we found alterations in quite a
few abundant plasma proteins. Lastly, fold change analysis
for each protein in equalized plasma samples could not be
performed as the CPLL technique usually normalizes the
abundances of most proteins. Nevertheless, this is the most
comprehensive study performed till date on the plasma
proteome in Rheumatic Mitral Stenosis.
Conclusion
The molecular events leading to disease development
are complex and diverse and remain incompletely char-
acterized so far. The identification, quantification and
functional characterization of proteins are essential to
fully understand these molecular events. Very few prote-
omic studies on rheumatic valve disease have been car-
ried out till date and none at all on stenotic mitral valve
disorder. Our results highlight that Rheumatic Mitral
Stenosis is an active inflammatory process which mani-
fests both inflammatory and thrombotic components.
Although our findings are purely exploratory, this study
provides an example of how one can attempt to identify
an entire population of plasma proteins that characterize
a disease state. Thus, label free plasma proteomic ana-
lysis in Rheumatic Mitral Stenosis for the very first time
proves to be a useful strategy to study proteins, some of
which might play important roles in the pathophysiology
of Mitral Stenosis. Hence, this protein profile may serve
as a focal point for future mechanistic studies. Besides
some of the proteins found to be differentially abundant
in this disorder may be candidate biomarkers for disease
diagnosis and prognosis for which validation studies in
individual patients in larger populations across multiple
centres need to be carried out. These results may help
to provide additional information about the molecular
mechanisms of Mitral Stenosis and improve the existing
diagnostic strategies.
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Ethics approval
The study protocol conformed to the principles of the
Declaration of Helsinki and was approved by the Institu-
tional Review Boards of the Indian Institute of Chemical
Biology, Kolkata and IPGME&R-SSKM, Kolkata, India.
Written informed consent was obtained from all subjects
prior to their inclusion in the above study.
Study design and population
The study population consisted of 54 subjects which in-
cluded 19 controls and 35 chronic Rheumatic Mitral
Stenosis patients. Moderate to severe Mitral Stenosis
subjects who visited Cardiothoracic and vascular surgery
(CTVS) department of the Institute of Post Graduate
Medical Education and Research- Seth Sukhlal Karnani
Memorial Hospital (IPGME&R-SSKM), Kolkata, India
were recruited into the study. Healthy individuals with
no apparent cardiac illness or history of coronary artery
disease or past history of rheumatic fever or any medica-
tion use were selected as controls and underwent the
same protocol. All controls had normal blood pressure,
cardiac function and lipid profile. They also had normal
fasting blood glucose levels.
Inclusion/Exclusion criteria
Subjects having clinically documented rheumatoid arthritis,
diabetes, hypertension, severe systemic illness, renal failure,
liver failure or any organic heart disease except Rheumatic
Heart Disease were excluded from the study. Even Rheu-
matic Heart Disease patients presenting with predomin-
antly stenotic or regurgitant lesions of the aortic valve or
having predominant regurgitation of the mitral valve were
excluded. Other exclusion criteria included malignancies,
other inflammatory and connective tissue disorders.
Echocardiography
Two dimensional transthoracic echocardiography was
performed on all subjects using commercially available
systems. Echocardiographic diagnosis of Rheumatic Mitral
Stenosis was done following the guidelines laid down in
the 2012 World Heart Federation criteria [55]. Left atrial
and left ventricular diameters both at systole and diastole
were assessed. Mitral valve area (MVA) was determined
both by planimetry and pressure half time (PHT)
methods. Pulmonary artery systolic pressure (PASP) was
also measured. Ejection fraction was determined by Simp-
son’s method. None of the subjects selected for the study
had heart failure as assessed by an ejection fraction ≤ 50%.
Clinical examination
All subjects were examined by physicians and their clin-
ical data entered in a structured pro forma. Symptoms
of patients were categorized according to the NYHAfunctional class. Systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were determined. Pulse rate
was observed and any irregularity was noted. Latest elec-
trocardiograms (ECGs) were evaluated.
Sample collection and processing
Peripheral venous blood (~7-8 ml) was drawn aseptically
from Mitral Stenosis patients (n = 35) and control sub-
jects (n = 19) during routine clinical assessment (RCA).
In the “discovery” or “proteomic analysis” phase, 6 pa-
tient samples and 6 control samples were employed for
profiling analyses. For better understanding, the demo-
graphics, disease severity as well as medication of these
6 selected patients are presented in Tables 2 and 3 re-
spectively and are indicated in italics. The remaining
plasma samples were used in the verification experi-
ments. Some of the control and patient samples used in
the profiling phase were also included in the verification
studies (Additional file 3). Blood samples were collected
from controls and from patients prior to mitral valve re-
placement surgery in sterile (13 × 75 mm× 3 ml) vacu-
tainers (BD, Franklin Lakes, NJ, USA) containing spray
dried K2 EDTA as anticoagulant. Plasma was obtained
by processing within 3 hours of blood collection. Briefly,
the tubes were rolled end to end for about 10 times
followed by centrifugation at 2000–2500 × g for 15 mins
at 4°C. The upper 2/3 part or the supernatant was col-
lected as plasma and aliquoted in 400-500 μl or less in
sterile 1.5 ml microcentrifuge tubes. Samples were la-
belled and immediately stored in −80°C or liquid nitro-
gen until further analysis. Repeated freeze-thaw cycles
were avoided. Protein concentrations of crude plasma
samples were determined using a Lowry assay [56].
Enrichment of the low abundance plasma proteome on
hexapeptide ligand library beads
To decrease sample complexity and to increase the sen-
sitivity of detection we used the CPLL technology. This
method is very reproducible, enabling the flow-through
fractions (medium to low abundant proteins) to be com-
bined after several elution steps in order to obtain the
amounts of protein necessary for high throughput prote-
omic analysis. Plasma samples collected from healthy
individuals (n = 3) and stenotic patients (n = 3) were
pooled and pre-treated with the ProteoMiner protein en-
richment kit (Bio-Rad Laboratories, Hercules, CA, USA)
according to the manufacturer’s instructions. The eluted
fractions from the patient and control spin columns
were pooled and stored at −20°C prior to analysis.
Protein precipitation, quantification and in-solution
trypsin digestion
Proteins obtained by the enrichment method were pre-
cipitated in four sample volumes of ice-cold acetone
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fuged at 14000 × g for 10 min and pellets were dissolved
in 100 μl of 20 mM NH4HCO3. Protein concentration
was determined by DC protein assay (Bio Rad, Hercules,
CA, USA) according to the manufacturer’s instructions.
For in-solution digestion, proteins (100 μg) from crude
and equalized plasmas were solubilized with 0.1% Rapi-
Gest SF (Waters Corporation, Milford, MA,USA) in
50 mM NH4HCO3 to enhance proteolytic cleavage. Pro-
teins were reduced and alkylated with 100 mM DTT at
37°C for 45–60 min and 200 mM iodoacetamide in the
dark at room temperature for 45–60 min, respectively.
The proteins were digested overnight (~16-18 hrs) with
sequencing grade porcine trypsin (Promega, Madison,
WI, USA) in 50:1 ratio at 37°C. The reaction was
stopped by incubating with 2 μl of 50% formic acid at
37°C for 20 minutes. The digest was vortexed and cen-
trifuged to collect the supernatant containing peptides.
LC-MSE
LC-MSE, a label free mass spectrometry based shotgun
proteomics technique was adopted for quantification of
differentially abundant proteins as described earlier [57].
UPLC conditions
400 ng of digested peptides after reconstituting in 3%
acetonitrile, 0.1% formic acid were injected into online
nanoACQUITY UPLC coupled to a QTOF, Synapt-
HDMS mass spectrometer (Waters Corporation, Mil-
ford, MA, USA). The peptides were separated by using a
BEH 130-C18 reversed phase column (1.7 μm x 75 μm x
250 mm) (Waters Corporation, Milford, MA, USA). The
binary solvent system used comprised 99.9% water and
0.1% formic acid (mobile phase A) and 99.9% aceto-
nitrile and 0.1% formic acid (mobile phase B). Peptides
were initially preconcentrated and desalted online at a
flow rate of 5 μl/min using a 5 μm Symmetry C18 trap-
ping column (internal diameter 180 mm, length 20 mm)
(Waters Corporation, Milford, MA,USA) with a 0.1% B.
After each injection, peptides were eluted into the Nano-
LockSpray ion source at a flow rate of 300 nL/min using
a gradient of 2– 40% B for 90 min. Then the column
was washed and equilibrated.
Mass spectrometry conditions
Q-TOF MS/MS was performed at a resolution of about
10000 full width half maximum (FWHM) using an ESI
interface. For instrument calibration, the external cali-
bration standard or lock mass [(GLU1)]-Fibrinopeptide
B,50 fmol/μl) was constantly infused by the NanoAC-
QUITY auxiliary pump at a constant flow rate of 500nL/
min at an interval of 20 secs (lock spray frequency) and
the mass error was less than 2 ppm. The lock mass data
were averaged for correction. The eluted peptide spectrawere acquired by Synapt HDMS (Q-TOF) in a positive V
mode in a scan mass range of 50–2000 m/z with a scan
time of 0.7 sec. The on-line eluted peptides were ana-
lyzed at both low collision energy (4 eV) and high colli-
sion energy (15-40 eV). The tryptic digests generated
either from crude or equalized plasma, were run in
triplicates.Protein identification
LC-MSE data analysis was performed with the Protein
Lynx Global Server 2.5.2 software (PLGS; Waters Cor-
poration, Milford, MA, USA). Preliminary searches were
made for protein identification against reviewed Homo
sapiens database (UniProtKB) using the search engine
Integrated protein lynx global server [58]. Precursor and
peptide fragment mass tolerance was selected “auto-
matic” in the PLGS workflow. PLGS identifies proteins
with less than 10–15 ppm for precursor and products
(50 ppm). Oxidation of methionine and carbamidometh-
ylation of cysteine were searched as variable and fixed
modifications, enzyme specificity was trypsin and upto
two missed cleavages were allowed. The false positive
rate was kept at 4% in the PLGS workflow. The theoret-
ical molecular mass (MW) and isoelectric point (pI)
were determined for each of the identified proteins using
ExPASy Bioinformatics Resource Portal (www.expasy.
org/compute_pi/). Only those proteins were considered
identified where a same protein was identified by PLGS
in all three technical replicates or in at least two of the
three runs. Proteins showing a trend of upregulation in
the proteomic analysis are shown in Additional file 4.Label free protein quantification
Label free protein quantification was done by MSE ap-
proach. As an internal detection control, 100 fmol of a di-
gest of yeast alcohol dehydrogenase [Swiss-Prot: P00330]
was spiked with the protein digest for quantification. Three
most intense peptides of the spiked protein were consid-
ered for quantification. Data was acquired in three technical
replicates and out of those the one which showed highest
nanogram concentration was used for normalization of
control and patient runs respectively. Accurate mass and
retention time matches of precursors were compared
across all LC-MS runs for label-free intensity based quanti-
tation. The ratio or fold change for each altered protein as
also the protein ratio p values for differential abundance
were computed by PLGS.Functional annotation of profiled proteins
Major functions of overlapping and differentially abun-
dant proteins were determined using the Swiss- Prot
database [59].
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Plasma concentrations of three selected proteins- α-2-HS-
glycoprotein (R&D Systems, Minneapolis, MN, USA),
clusterin (R&D Systems, Minneapolis, MN, USA) and
vitronectin (Takara Bio Inc. Shiga, Japan), were determined
in individual patient and control plasma by enzyme im-
munoassay (EIA) using commercial assay systems following
the manufacturer’s protocol. Duplicate measurements were
taken and averaged. Plasma α-2-HS- glycoprotein was
assessed in 10 controls and 18 patient subjects while clus-
terin was measured in 10 controls and 15 diseased subjects.
Plasma vitronectin was measured in 10 controls and 14
patients. Plasma apolipoprotein AI concentrations were
quantitatively assessed in 12 control and 13 patient plasma
samples using an immunoturbidimetric assay (Randox La-
boratories). No detectable cross reaction or interference
was observed for any of the four proteins assayed. The
minimum detection sensitivities ranged from 0.16-1.74 ng/
ml for α-2-HS- glycoprotein and 0.06-1.05 ng/ml for clus-
terin while for vitronectin it was 5 ng/ml. The inter and
intra-assay variations ranged between 2.2-9.6% and
4.9-6.3% for vitronectin, 6.8-8.4% and 3.4-3.7% for
clusterin and 7.3-8.4% and 3.9-4.9% for α-2-HS-glyco-
protein respectively.Identification of pathways associated with rheumatic
mitral stenosis
In order to better understand the relevance of the
identified proteins in the disease context, pathway ana-
lysis was done using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) bio-
informatics resources (david.abcc.ncifcrf.gov/tools.jsp).
For this, UniProt human accession numbers were
uploaded as a “Gene List” with Identifier selected as
“UNIPROT_ACCESSION”. Finally, the DAVID tool
[60] was used as an interface to the KEGG [61] path-
way repository at Kyoto University to generate path-
way diagrams that illustrate some possible association
of the common and altered proteins with the patho-
physiology of Rheumatic Mitral Stenosis.Histopathology analysis
Anterior leaflets of mitral valve tissue samples, from
subjects undergoing valve replacement and from post
mortem control subjects without any known history of
cardiovascular disease, were collected and fixed in 10%
formalin. Tissue samples were then embedded in paraf-
fin and 5 μm thick sections were prepared. Sections
were then stained with HE stain (Sigma Chemical Co.,
St Louis, MO, USA) as described earlier [62]. Sections
were examined under an Olympus BX51 (Olympus Cor-
poration, Tokyo, Japan) microscope and images were
captured with a digital camera attached to it.Analysis of protein interaction networks
Protein interaction networks for the differentially abun-
dant as well as the common proteins were computed by
STRING version 9.1 (string-db.org/). STRING nodes are
proteins and edges are the predicted functional associa-
tions based on primary databases such as KEGG and GO,
and primary literature. STRING predicts these interac-
tions based on neighbourhood, gene fusion products,
homology and similarity of coexpression patterning. Net-
work interaction scores for each node are expressed as a
joint probability derived from curated databases of experi-
mental information, text mining and computationally pre-
dicted by genetic proximity [63]. In this study, STRING
networks were calculated with the following default set-
tings - medium confidence score: 0.400, network depth: 0
and up to 50 interactions.
Statistical analysis
Data are expressed as mean ± standard error of mean
(SEM). Categorical variables were analysed by Chi square
(χ2) or Fisher’s exact test. Differences between the control
and patient groups were tested by a Student’s t- test for
unpaired data once normality was demonstrated by
Shapiro Wilk test. Venn diagram was done with Microsoft
excel 2010. A probability value < 0.05 was considered sta-
tistically significant.
Additional files
Additional file 1: List of proteins identified in plasma samples of
controls.
Additional file 2: List of proteins identified in plasma samples of
Rheumatic Mitral Stenosis.
Additional file 3: Details of profiling and verification samples.
Additional file 4: List of proteins showing a trend of upregulation
in the proteomic analysis.
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